Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Shares Outstanding (Weighted Average): 2023-2025

Historic Shares Outstanding (Weighted Average) for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $76.2 million.

  • CG Oncology's Shares Outstanding (Weighted Average) rose 13.67% to $76.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year increase of 13.67%. This contributed to the annual value of $67.6 million for FY2024, which is 55.53% up from last year.
  • As of Q3 2025, CG Oncology's Shares Outstanding (Weighted Average) stood at $76.2 million, which was up 0.03% from $76.2 million recorded in Q2 2025.
  • CG Oncology's Shares Outstanding (Weighted Average)'s 5-year high stood at $76.2 million during Q3 2025, with a 5-year trough of $43.5 million in Q1 2023.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $61.0 million, with a median of $66.6 million in 2024.
  • Data for CG Oncology's Shares Outstanding (Weighted Average) shows a peak YoY soared of 55.53% (in 2024) over the last 5 years.
  • CG Oncology's Shares Outstanding (Weighted Average) (Quarterly) stood at $43.5 million in 2023, then spiked by 55.53% to $67.6 million in 2024, then climbed by 13.67% to $76.2 million in 2025.
  • Its last three reported values are $76.2 million in Q3 2025, $76.2 million for Q2 2025, and $76.2 million during Q1 2025.